![](/img/cover-not-exists.png)
5T4-specific antibody responses are associated with survival in a phase II trial of renal cell carcinoma patients vaccinated with modified vaccinia Ankara delivering the tumour antigen 5T4 in combination with low-dose IL-2
W.H. Shingler, S. Naylor, J. Hernandez-McClain, R.J. Amato, J. Jac, J. Willis, S. Saxena, R. HarropVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)71703-8
File:
PDF, 89 KB
english, 2008